Combined metabolic activators improve cognitive functions in AD patients

Insights and discussion from the cutting edge with reference to journal articles and other research papers.
Post Reply
Senior Contributor
Senior Contributor
Posts: 554
Joined: Mon Oct 30, 2017 6:19 pm

Combined metabolic activators improve cognitive functions in AD patients

Post by Plumster »

Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals. CMA promotes mitochondrial fatty acid uptake from the cytosol, facilitates fatty acid oxidation in the mitochondria, and alleviates oxidative stress.

Here, we designed a randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD patients. One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%). AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84. The primary endpoint was the difference in the cognitive function and daily living activity scores between the placebo and the treatment arms. The secondary aim of this study was to evaluate the safety and tolerability of CMA. A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efficacy of the CMA in AD patients.

We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline (P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment.

Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.
Full link to article here
e3/4 MTHFR C677T/A1298C COMT V158M++ COMT H62H++ MTRR A66G ++ HLA DR
Senior Contributor
Senior Contributor
Posts: 288
Joined: Tue Oct 02, 2018 12:32 pm
Location: Central Florida

Re: Combined metabolic activators improve cognitive functions in AD patients

Post by BrianR »

Interesting - thanks Plumster.

I wonder if they have the resources to proceed to a meaningful phase 3 trial in Turkey or somewhere else in the EU? (Maybe even including ApoE genotyping this time.) It's difficult for me to believe that anyone would fund a large phase 3 trial in the US for a relatively generic compound. But perhaps it could be available OTC in the US.

I note that the compound was administered orally, thus mediated through the gut. It would be useful to understand the range of metabolites produced over a larger population with many different flavors of gut microbiota.
Post Reply